Korean Diabetes Journal 2000;24(5):587-602.
Published online January 1, 2001.
Efficacy and Safety of beraprost sodium in Type 2 Diabetic Subjects Complicated with Arteriosclerosis Obliterans (ASO): A Prospective, Multicenter, Open Clinical Study.
Yeon Sahng Oh, Young Deuk Song, Moon Kyu Lee, Young Seol Kim, Ho Young Son
1Department of Internal Medicine, College of Medicine, Chung-Ang University.
2Department of Internal Medicine, College of Medicine,Yonsei University.
3Department of Internal Medicine, College of Medicine,Sungkyunkwan University.
4Department of Internal Medicine, College of Medicine,Kyung Hee University.
5Department of Internal Medicine, College of Medicine,Catholic University.
Abstract
BACKGROUND
Beraprost sodium (BPS) is a new stable, orally active prostaglandin I2 analogue with antiplatelet and vasodilating properties. We performed an prospective, multicenter, open clinical trial to assess the efficacy and safety of BPS in type 2 diabetic patients complicated with arteriosclerosis obliterans (ASO). METHOD: We recruited 34 type 2 diabetic patients complicated with ASO at 5 different university hospitals. Patients received BPS 40 g tid for 6-week. Patients performed a subjective and objective assessment of treatment usefulness at 2- and 6-week. Safety was assessed by obtaining clinical data and history. RESULTS: There was a significant difference between before and after treatment for changes regarding the items "chillness", "numbness" and "rest pain". An improve ment in intermittent claudication distance at the 2-or 4-week interval was achieved. Ankle Pressure Index (API) was not statistically different. The side effects including fever, myalgia, indigestion were subtle and the patients' compliance is good. CONCLUSION: These results show that BSP is an effective and safe symptomatic treatment of Type 2 diabetic patients with ASO.
Key Words: Beraprost sodium, Type 2 Diabetes Mellitus, Arteriosclerosis Obliterans (ASO)


ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-2104, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea​
Tel: +82-2-714-9064    Fax: +82-2-714-9084    E-mail: diabetes@kams.or.kr                

Copyright © 2021 by Korean Diabetes Association.

Developed in M2PI

Close layer